190 related articles for article (PubMed ID: 23769437)
21. Increased expression of sex determining region Y-box 11 (SOX11) in cutaneous malignant melanoma.
Jian J; Guoying W; Jing Z
J Int Med Res; 2013 Aug; 41(4):1221-7. PubMed ID: 23867449
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract][Full Text] [Related]
23. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
24. Expression analysis of ovostatin 2 reveals its involvement in proliferation, invasion and angiogenesis of cutaneous malignant melanoma.
Huang YX; Qi J; Wang HS; Shao XB; Zeng XS; Li AM; Xu XL; Sun JF
J Dermatol; 2013 Nov; 40(11):901-10. PubMed ID: 24112097
[TBL] [Abstract][Full Text] [Related]
25. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
26. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
[TBL] [Abstract][Full Text] [Related]
27. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
29. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
31. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma.
Shimizu A; Kaira K; Yasuda M; Asao T; Ishikawa O
Neoplasma; 2016; 63(2):282-7. PubMed ID: 26774151
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.
Oba J; Nakahara T; Hayashida S; Kido M; Xie L; Takahara M; Uchi H; Miyazaki S; Abe T; Hagihara A; Moroi Y; Furue M
J Am Acad Dermatol; 2011 Dec; 65(6):1152-60. PubMed ID: 21700362
[TBL] [Abstract][Full Text] [Related]
34. Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma.
Messeguer F; Agustí-Mejías A; Traves V; Requena C; Alegre V; Guillén C; Oliver V; Nagore E
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):436-41. PubMed ID: 22303982
[TBL] [Abstract][Full Text] [Related]
35. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness.
Morton DL; Davtyan DG; Wanek LA; Foshag LJ; Cochran AJ
Cancer; 1993 Jun; 71(11):3737-43. PubMed ID: 8490924
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in patients with localized primary cutaneous melanoma.
Mervic L
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(2):27-31. PubMed ID: 23000937
[TBL] [Abstract][Full Text] [Related]
37. Prognosis associated with cutaneous melanoma metastases.
Pan Y; Haydon AM; McLean CA; McDonald PB; Kelly JW
Australas J Dermatol; 2015 Feb; 56(1):25-8. PubMed ID: 25688698
[TBL] [Abstract][Full Text] [Related]
38. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma.
Murali R; Hughes MT; Fitzgerald P; Thompson JF; Scolyer RA
Ann Surg; 2009 Apr; 249(4):641-7. PubMed ID: 19300224
[TBL] [Abstract][Full Text] [Related]
39. Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
Karjalainen JM; Eskelinen MJ; Nordling S; Lipponen PK; Alhava EM; Kosma VM
Br J Cancer; 1998 Jun; 77(11):1917-25. PubMed ID: 9667668
[TBL] [Abstract][Full Text] [Related]
40. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
